Firms To Watch: Healthcare: life sciences

Freshfields Bruckhaus Deringer LLP has aggressively expanded its life sciences team this year, bringing in New York-based transactional and IP expert Adam Golden from Hogan Lovells and Silicon Valley-based digital health expert Vinita Kailasanath from Arnold & Porter.
Irell & Manella LLP’s team is known for its excellent patent advice to genomics companies, with Los Angeles-based team head Morgan Chu acting for clients in a number of high-value trade secrets litigations.
Regulatory experts Loeb & Loeb LLP are known for their strong FDA guidance and exceptional patent litigation abilities, with new York-based co-heads Scott Liebman, Fran Stoller and Mark Waddell providing expertise on FDA compliance, transactions and IP litigation respectively. 

Healthcare: life sciences in United States

Arnold & Porter

With a client base ranging from multinational biopharmaceutical companies to small medical device and biotech firms, Arnold & Porter maintains its leadership in the life sciences sector. Clients are offered a broad range of service, with transactions, IP regulations, data privacy, and litigation being a part of the practice’s portfolio. It has also spearheaded legal work on Covid-19 treatments, advising AstraZeneca on funding and distribution agreements for its vaccine formula. Litigation has also been a highlight this year acting on cases related to the opioid epidemic as well as industry-leading patent cases. Daniel Kracov and Allison Shuren lead the team from Washington DC, respectively advising on FDA biomedical compliance and fraud & abuse defense. Also in the DC office are longtime pricing expert Jeffrey Handwerker, and regulatory attorneys Mahnu Davar and Ariane Horn. Kristin Hicks and Murad Hussain are key names for FCA disputes, while New York-based Anand Agneshwar and Daniel DiNapoli act on patent and product liability cases. Also well regarded is California-based Deborah Fishman who acts in patent trials at the district and federal appeals court levels.

Practice head(s):

Dan Kracov


‘The A&P is extremely knowledgeable in their field but, more importantly, extremely client-focused and responsive. I ALWAYS feel like I’m their most important client – even if I know I’m not.’

‘Jeff Handwerker is one of the most plugged-in lawyers around. He has advised us on numerous matters over the years where he knew what was coming and helped us plan so we could avoid issues today and in the future.’

‘Simply the most knowledgeable Life Sciences practice in the United States.’

‘Kristin Hicks is one of the top government pricing lawyers – she provides extremely specific, timely and practical advice. A great listener and communicator overall, she can take incredibly complex concepts and explain them clearly and succinctly. Jeff Handwerker knows the pharmaceutical industry better than anyone – the best lawyer in the sector as he provides regulatory advice, handles high stakes litigation and influences legislative policy.’

‘A&P has the best fraud and abuse, and government price reporting practice in the life sciences industry in my opinion. They have also supported Sanofi very well in congressional investigations. We appreciate the terrific litigation team at A&P, who have handled our most significant matters. Lastly, we have used A&P in our real estate matters and have been pleased. A&P is very willing to engage with alternative fee arrangements, including fixed fees, capped fees and success bonuses. A&P is committed to diversity, and has put more diverse lawyers on our matters.’

‘The A&P lawyers we work with is very proactive. They provide us with actionable information first or that we don’t receive from others. They understand our business, products and services. They provide business-focused, pragmatic and solutions-oriented counseling.’

Key clients


Pharmaceutical Research and Manufacturers of America (PhRMA)




Thermo Fisher


SK Capital

Bristol-Myers Squibb Company



Eisai, Inc.

Novo Nordisk

Vertex Pharmaceuticals


Sanofi and Regeneron


Work highlights

  • Representing Pfizer and related companies on product liability and IP litigation, as well as regulatory and antitrust counseling.
  • Represented Novartis, its predecessors and its affiliates in the Americas and Europe.
  • Advising Bayer and its related entities dates on a long-standing basis.

Cooley LLP

The life sciences team at Cooley LLP ‘draw on their extensive experience’ with major life sciences clients to act on market-leading transactions. Through its traditional work base advising on capital markets offerings, it has expanded its focus on licensing agreements, collaborations and product sales, including Palo Alto-based Marya Postner‘s advice on a $1.2bn sale of an antibody program to Novo Nordisk. The team also has experience advising on patent prosecutions, as well as securities and commercial litigation. San Diego-based Kay Chandler and Boston-based Christian Plaza co-lead the team, respectively providing expertise on major M&A and capital markets transactions. New York-based Ivor Elrifi offers significant patent advice to his clients, on both contentious and non-contentious matters. Kate Hillier, who works in both Palo Alto and Seattle, is known for her experience providing advice to growing companies developing biopharmaceutical and digital health products. On financing matters, Palo Alto-based Laura Berezin and Reston-based Ken Krisko are key names.

Practice head(s):

Kay Chandler; Christian Plaza

Other key lawyers:

Ivor Elrifi; Kate Hillier; Laura Berezin; Ken Krisko; Marya Postner


‘I have found the Cooley life sciences team to excel in providing practical legal advice. With such a large life sciences client base, they are able to draw on their extensive experience to tailor solutions and approaches.’

‘I have worked with Kay Chandler on numerous life sciences partnering transactions across a number of clients over the past 20 years and consider her to be an exceptional practitioner. She brings a vast depth of experience to the table, has a very pragmatic approach, and is an effective negotiator. I could not recommend her highly enough.’

Key clients

Five Prime

Prothena Corporation plc

Vaccibody AS

Artiva Biotherapeutics, Inc.

Ovid Therapeutics Inc.

Vir Biotechnology

Molecular Partners AG

HorizonTherapeutics plc

Senti Biosciences

Turning Point Therapeutics, Inc.

NGM Biopharmaceuticals, Inc.


Beam Therapeutics, Inc.

Mirum Pharmaceuticals, Inc.

Work highlights

  • Advised Five Prime Therapeutics on its $1.9 billion agreement to sell to Amgen.
  • Advised Vaccibody on its exclusive worldwide license and collaboration agreement with Roche Group member Genentech for Neoantigen vaccine development.
  • Represented Artiva in an exclusive worldwide collaboration and license agreement with Merck to develop novel chimeric antigen receptor-natural killer cell therapies.

Latham & Watkins LLP

Latham & Watkins LLP is praised for its ‘unparalleled’ life sciences transactional capabilities, offering expertise on M&A and capital markets transactions across multiple jurisdictions. It has been heavily involved in the SPAC market, advising biotech, clinical research and therapy companies on over $20bn worth of combined listings, in addition to a strong IPO presence. On the regulatory front, the team is well known for its FDA practice, advising on drug approvals, clinical trials and exclusivity rights for producers. Most notably, the team has acted for Catalyst Pharmaceuticals to receive exclusivity rights for its ‘orphan drug’ Firdapse. Washington DC-based Elizabeth Richards, Ben Haas and John Manthei all offer regulatory expertise. Patent litigation is another expertise of the team, with DC-based Michael Morin and Adam Perlman, and New York-based Arlene Chow and Ernest Yakob key names to note. Manthei co-leads the team, alongside Silicon Valley-based transactional expert Judith Hasko and Chicago-based litigator Terra Reynolds. Silicon Valley-based Brian Cuneo is known for his advice to emerging companies and venture capital firms.

Practice head(s):

Brian Cuneo; Michael Morin; Terra Reynolds; Robbie McLaren; John Manthei; Judith Hasko


‘I’ve dealt with Latham & Watkins LLP through setting up legal contracts for the company I currently work with. Great explanations given by the Elizabeth Richards and Jeremiah Wolsk, in terms of being able to clearly explain to a non-legal person the implications of phrases etc within contracts and what it means.’

‘Elizabeth Richards and Jeremiah Wolsk are the people who I have worked with the most. Great to work with, really friendly and down to earth. They don’t waste your time.’

‘Very sophisticated team. Able to analyze complex strategic issues.’

‘The Latham team has a fantastic reputation in the industry and is well respect by all of the key players in the market. Their experience with transactions in the life sciences space is unparalleled and they are involved in all of the major life science deals. They are exceptional at creating leverage for their clients and extracting top dollar for their clients in transactions.’

‘Tom Malone is an exceptional attorney and business partner. Tom is one of the smartest and most savvy attorneys I have ever worked with and he has unparalleled knowledge in the life science market. Tom knows all of the players in the market and is exceptional at negotiating maximum value for his clients.’

Key clients

Aligos Therapeutics, Inc.

Alphatec Holdings, Inc.

Alpha Tau Medical

American Renal Holdings, Inc.


Angion Biomedica Corp.

ATAI Life Sciences N.V.

Ayala Pharmaceuticals, Inc.

Berkeley Lights

Biomea Fusion

Bioventus Inc.

Boston Scientific Corporation

Chardan Healthcare Acquisition 2 Corp.

Crinetics Pharmaceuticals, Inc.

Cryoport, Inc.

eFFECTOR Therapeutics, Inc.

Environmental Impact Acquisition Corp.

Erasca, Inc.

Ginkgo Bioworks, Inc.

Grail, Inc.

Gritstone bio, Inc.

Icosavax, Inc.

Immuneering Corporation

Itamar Medical ltd.

Khosla Ventures Acquisition Co.

Nestlé USA, Inc.

Work highlights

  • Represented Amgen in its $1.2bn offering of senior notes.
  • Advising Nestle USA on its $5.75bn acquisition of supplement manufacturer The Bountiful Company.
  • Represented Catalyst Pharmaceuticals in a dispute concerning the exclusivity of its drug Firdapse.


Well known for the strength of its global  life sciences practice, Goodwin offers US clients advice on financing transactions and regulatory approvals. The team has been strongly involved in capital markets advising on multimillion-dollar IPOs and a number of follow-on financings. Its M&A capacity is also strong with Boston-based Stuart Cable and co-head Mitchell Bloom advising Myokardia on its $13.1bn sale to Bristol Meyers Squibb. The FDA team, meanwhile, advises on pre and post-market matters,  with a recently established late-stage drug division established. It also has expanded its patent litigation offering with the hiring of Los Angeles-based Kristin Havranek from Wilson Sonsini Goodrich & Rosati in August 2021. San Francisco-based Can Cui joined from Morrison Foerster in March 2021, with a practice advising on regulatory and transactional matters in the Chinese market. Kingsley Taft co-leads the team from Boston, advising on licensing and collaborations with Robert Puopolo. Also noteworthy are Washington DC-based Hatch-Waxman expert Alexander Varond, and Boston-based emerging companies expert Danielle Lauzon.

Practice head(s):

Mitchell Bloom; Kingsley Taft

Other key lawyers:

Stuart Cable; Kristin Havranek; Can Cui; Robert Puopolo; Alexander Varond; Danielle Lauzon


‘A very experienced and pragmatic team with a very obvious focus on their clients’ satisfaction above all.’

‘Rob Puopolo – relaxed and experienced – his team – including Marishka deToy have been pretty much faultless through our IPO and subsequently.’

‘Goodwin is our corporate counsel. Their team is experienced, responsive, resourceful, collaborative, nimble and thoughtful.

Key clients

Moderna, Inc.

BeiGene, Ltd.

CRISPR Therapeutics AG


Blueprint Medicines

Alnylam Pharmaceuticals


Monte Rosa Therapeutics


Centessa Pharmaceuticals

Work highlights

  • Advising A 5AM Ventures in its role as lead investor in the $70m Series A financing of genetics company Ensoma.
  • Advising Centessa Pharmaceuticals on its $379.5m initial public offering.
  • Advised MyoKardia in its $13.1bn sale to Bristol Myers Squibb.

Hogan Lovells US LLP

In addition to ‘outstanding expertise with small to mid-sized public biotech and pharma companies’ Hogan Lovells US LLP is also able to act for international pharmaceuticals companies. The team’s regulatory capacity is a key factor in this, advising on FDA clearances and post-approval compliance. IP is another area of expertise, primarily in transactions where the team provides diligence support in major capital markets and M&A matters and acts on IP litigation. It also has a strong product liability offering led by Baltimore-based Lauren Colton, which advises on medical devices and pharmaceuticals. The Washington DC office is led by biologics risk evaluation expert Lynn Mehler, experienced biopharmaceutical startup advisor Philip Katz and Randy Prebula, who gives regulatory advice to medical device and technology companies. Also DC-based is David Fox, who is known for his Hatch Waxman compliance expertise. Philadelphia-based team leader Steve Abrams is known for transactional work. Also recommended are DC-based Anishiya Abrol and Philadephia-based Blake Wilson.

Practice head(s):

Steve Abrams; Lynn Mehler; Jane Summerfield; Philip Katz; Randy Prebula; Lauren Colton

Other key lawyers:

Anishiya Abrol; Blake Wilson.


Outstanding expertise with small to mid-sized public biotech and pharma companies. The team\’s experience proves very helpful, especially in connection with SEC filings and equity offerings.

Steve Abrams and Stephen Nicolai stand out for their expertise representing small to mid-sized public biotech and pharma companies.

Key clients

Baxter International Inc.

Biom’Up SA


Exact Sciences

Jazz Pharmaceuticals



Novocure Ltd.


The University of Pennsylvania

Work highlights

  • Advising Pyxis Oncology on key patent prosecution, strategic counseling, and IP due diligence.
  • Advised Lucira Health on its Emergency Use Authorization submissions for the first rapid, at-home test systems for Influenza and SARS-CoV-2 viruses.
  • Advised Memic in its regulatory strategy and submissions to secure FDA market authorization for its Hominis Surgical System.

King & Spalding LLP

King & Spalding LLP offering is noted for its FDA practice, which advises pharmaceutical, biotech and medical device companies on a product’s full lifespan. For early life products and companies, the team offers product development and approval advice, as well as corporate advice to young businesses. The team offers exceptional IP services to developed clients, with an emphasis on Hatch-Waxman, PTAB and Biologics litigation and exclusivity arrangements. It also offers a government relations and investigations team, which advises leading clients such as Pfizer on congressional inquiries, and anti-kickback cases. The team is led out of Washington DC by compliance expert Nikki Reeves, fraud litigator Seth Lundy and Mark Brown, who advises on matters leading to product liability suits. Silicon Valley-based Laura Bushnell is ‘deeply connected in the M&A, securities and financings areas’ and advises a number of start-ups. DC-based regulatory specialists Lisa Dwyer and Brian Bohnenkamp, pharmaceutical pricing expert John Shakow and white-collar litigator Mark Jensen are also recommended.

Practice head(s):

Nikki Reeves; Mark Brown; Seth Lundy

Other key lawyers:

Laura Bushnell; Lisa Dwyer; Brian Bohnenkamp; John Shakow; Mark Jensen


‘Cohesive team approach led by one partner as my client relationship contact. Strong background in healthcare space, with securities matters, financings, compliance and privacy issues.’

‘Laura Bushnell is our main relationship partner, and she is responsive and deeply connected in the M&A, securities and financings areas where our company resides. She is excellent at connecting us with her partners on a variety of matters.’

Key clients


ACADIA Pharmaceuticals

Allergan, Inc.

Amarin Corporation

Amryt Pharmaceuticals

Baxter International


Bristol Myers Squibb

Carl Zeiss Vision

Coloplast Corporation

Eli Lilly

EMD Serono

Exact Sciences


HeartFlow, Inc.


Hope Medical Enterprises, Inc. d/b/a/ Hope Pharmaceuticals

Imperative Care

Integra LifeSciences

Invacare Corporation


LEO Pharma, Inc.


Myra Medical

Novo Nordisk




PolarityTE, Inc.



Takeda Pharmaceuticals

Tandem Diabetes

Teleflex, Inc.


Zimmer Biomet

Work highlights

  • Advised Pfizer inc on congressional inquiries related to its COVID-19 vaccine development.
  • Represented Terumo Cardiovascular Systems in securing a court order to vacate and extinguish their 10-year Consent Decree in proceedings against the DOJ and FTC.
  • Advised HeartFlow Holding, Inc., in its SPAC business combination agreement to go public on the NYSE at a value of $2.4bn.

McDermott Will & Emery LLP

McDermott Will & Emery LLP has bolstered its broad life sciences team with a number of major lateral hires. Most notable in this is its expansion of the IP team, bringing new California-based practice co-head Douglas Carsten from Wilson Sonsini Goodrich & Rosati, expanding the firm’s litigation bench, which offers trial and arbitration services for patent disputes. Its transactional team has also continued to grow, with growing expertise in licensing and collaborations matters based out of the Chicago, Los Angeles and Atlanta offices. Another core element of the offering is regulatory work, with Washington DC-based co-head Vernessa Pollard advising on clinical research, marketing and post-market compliance. Also noteworthy are Boston-based IP experts Sarah Chapin Columbia and Michael Siekman, and Silicon Valley litigator William Gaede.

Practice head(s):

Vernessa Pollard; Doug Carsten

Other key lawyers:

Sarah Chapin Columbia; Michael Siekman; William Gaede; Thomas Steindler; Byron Kalogerou


‘Pleasure working with this firm due to their legal acumen, ability to quickly understand complex technologies, and zeal for their client’s matters. In addition, they provide business-oriented legal advice rather than merely focusing on the legal questions at issue.’

‘Thomas Steindler – Partner – Exceptional leader and exactly the attorney you want when dealing with aggressive opposing parties.

‘Partner Byron Kalogerou has established a good team around them. If one person isn’t available, the other continues without dropping the ball.’

Key clients

10x Genomics Inc.

Amgen Inc.

Assertio Therapeutics

Aurinia Pharmaceuticals

Bausch Health US



Charles River Laboratories

CRISPR Therapeutics, Inc.

Enhanced Healthcare Partners


Heron Therapeutics

Immunex Corporation

Impulse Dynamics

KAI Pharmaceuticals

Kymab Limited

Lyell Immunopharma, Inc.

Mallinckrodt Pharmaceuticals


Merck Global Health Innovation Fund

Michelin SCA/Solesis

Mylan Pharmaceuticals Inc./Mylan GmbH

Natera, Inc.


Origenis GmbH

Outspace Bio


Public Pension Capital

Quidel Corporation


Specifica, Inc.

United Therapeutics

Walking Fish Therapeutics

Windrose Health Investors

Work highlights

  • Advised Medline Industries Inc in its sale to a consortium of private equity firms led by Blackstone, Carlyle and Hellman & Friedman.
  • Represented REGENXBIO in a $1.8bn strategic partnership with AbbVie.
  • Represented Amgen in its long-fought battle with Sanofi and Regeneron over new cholesterol drugs.

Morgan, Lewis & Bockius LLP

Morgan, Lewis & Bockius LLP is able ‘to shift quickly from litigation focus to compliance focus’ and assist in building corporate structures for life sciences clients. The team is particularly known for its work on research collaboration and licensing agreements, advising both emerging companies and pharmaceutical groups. It also provides M&A and capital markets advice. Its IP offering is equally notable, offering litigation support for small molecule, biologic and medical technology products, with Chicago-based co-head Michael Abernathy obtaining an appellate victory against Genentech’s hemophilia antibody treatment a key example. Kathleen Sanzo leads the FDA practice from Washington DC, offering broad advice on product development, approval and clinical testing. San Francisco-based co-head Jeffry Mann , primarily acts on IP asset management. SF-based Benjamin Pensak leads the transactional team, with Princeton-based Alan Leeds offering experience with venture capital. Also noteworthy is Washington DC-based Michele Buenafe, who advises on Medtech and digital health regulations.

Practice head(s):

Michael Abernathy; Kathleen Sanzo; Alan Leeds

Other key lawyers:

Michele Buenafe; Benjamin Pensak; Jeffry Mann; Amanda Goceljak; Jackie Berman; Dennis Gucciardo.


‘My experience with Morgan-Lewis has been very positive. They are a well-rounded firm with expertise across multiple aspects of the medical device industry.’

‘Dennis Gucciardo is one of the best FDA attorneys I have worked with in my 20-year career in Medical Device Quality and Regulatory Affairs. Not only does he know the applicable laws, he is always responsive to requests. Dennis is also great at brainstorming the best regulatory pathway when dealing with unique issues.’

‘Morgan Lewis’s healthcare and regulatory practice is second to none. They recruited the government lawyers necessary to navigate clients through these capricious times. They are willing to shift quickly from litigation focus to compliance focus and will assist in training and building corporate structures.’

‘Kathy Sanzo offers spot-on, non-filtered advice that gives business colleagues confidence in the law firm as well as the in-house department.’

‘Strong life sciences emphasis across various groups (e.g., transactional, regulatory).’

‘Amanda Goceljak is excellent at life science transactional work, particularly collaborations and licensing. Jackie Berman is sharp, presents well to management, and provides practical solutions for regulatory issues.’

Key clients

Eli Lilly and Co.


JC Medical, Inc.

Shiseido Americas Corporation


Zimmer Biomet


HP, Inc.

Takeda Pharmaceutical Co.

Work highlights

  • Represented Eli Lilly and Co. in its license, development, and commercialization agreement with Asahi Kasei Pharma Corp.
  • Represented Takeda’s affiliate Baxalta in a lawsuit against Genentech and its bispecific antibody drug Hemlibra®.
  • Advising JC Medical in expanding and developing its patent portfolio in the US and throughout the world.

Ropes & Gray LLP

Ropes & Gray LLP‘s healthcare team has ‘very specific expertise in niche investment classes,’ and is known as a go-to firm on major transactions. M&A is a key area of experience, having advised Acceleron on its $11.5bn sale to Merck, with the team also able to act in strategic affiliations and financing agreements. Its dedicated regulatory arm is known for its work on clinical trials and drug pricing matters, with a growing emphasis on digital health. Litigation is another key strength, with the team offering distinct practices in Hatch-Waxman litigation and broader contentious corporate support focused on life sciences clients. The team’s Boston office is a source for many leading attorneys in the sector, including transactional IP expert David McIntosh, Marc Rubenstein, who advises clients on collaboration agreements and M&A chair Chris Comeau. Silicon Valley-based Megan Baca is a key adviser to digital health companies. Washington DC-based Gregory Levine advises on FDA regulations, with an emphasis on the therapeutics and diagnostics segments.

Practice head(s):

Gregory Levine; Marc Rubenstein

Other key lawyers:

Chris Comeau; Megan Baca; Arthur Mok; Alyce Chen; Brad Flint; Geoffrey Lin


‘The team at Ropes has excellent expertise in the Healthcare sector as well as very specific expertise in niche investment classes. The team is very knowledgeable and has the institutional expertise that they can pull in internal experts as necessary to address very specific questions relating to IP, bankruptcy, etc.’

‘Megan Baca is an exceptional lawyer. Knowledgeable, responsive, and very high integrity.’

‘Ropes has great partners and associates with experience in the life sciences sector across all areas, including IP, regulatory, VC deals, IPOs and M&A.’

‘Arthur Mok is very responsive, thoughtful and knowledgeable and has a breadth of experience, not only in the Asia market, but on deals and corporate issues in general. I trust his advice.’

‘Geoffrey Lin is very responsive and thoughtful in the negotiation of licensing agreements. He and his team are able to turn documents quickly to produce excellent work product.’

‘Alyce Chen is an outstanding associate–very responsive, detail-oriented, has good judgment.’

‘Brad Flint is very responsive, gives very helpful advice and has a good sense of what’s market in the VC life sciences deal space.’

‘The Ropes & Gray IP licensing group is the best in the business. Creative thinkers, highly attuned to issues, creative when they have to be, and extremely dependable.’

Key clients

Upsher-Smith Labs

ArcherDX, Inc.



Cyteir Therapeutics, Inc.

National Resilience, Inc.

Prevail Therapeutics



Shape Therapeutics

Work highlights

  • Advising Acceleron in its $11.5bn sale to Merck & Co.
  • Represented Pfizer Inc. in its $2.26bn acquisition of Trillium Therapeutics Inc.
  • Represented Novavax in connection with the negotiation of multiple agreements related to the development and supply of its proprietary COVID-19 vaccine.

Weil, Gotshal & Manges LLP

Weil, Gotshal & Manges LLP is known for its contentious work, advising on both commercial and criminal litigation, offering particular expertise in patent litigation, where it advises clients such as Regeneron and Johnson & Johnson on the defense of their IP portfolio. The team also acts on government investigations and product liability cases. On the corporate side, the practice advises larger pharmaceutical and technology companies on their acquisitions of smaller, innovative manufacturers. It also has experience acting on Strategic alliances and licensing agreements. The New York office hosts significant portions of the IP team, including co-head Elizabeth Weiswasser, who acts on major patent litigation, and Jeffrey Osterman, who advises on IP aspects of transactions. Silicon Valley-based Edward Reines is also well regarded for his IP and corporate disputes expertise. Derek Walter is based in the same office.

Practice head(s):

Edward Reines; Elizabeth Weiswasser

Other key lawyers:

Jeffrey Osterman; Derek Walter

Key clients


Johnson & Johnson



Guardant Health


Bio-Rad Laboratories

Pacific Biosciences

Regeneron Pharmaceuticals

Eli Lilly

Quest Diagnostics

Work highlights

  • Representing Regeneron in patent and antitrust litigation against Novartis.
  • Represented Bio-Rad Laboratories in its six-year battle with competitor 10X Genomics.
  • Advised Eli Lilly in connection with the technology and IP aspects of its $1.25bn research and collaboration agreement with MiNA Therapeutics and $1bn acquisition of Prevail Therapeutics.

Dechert LLP

With experience advising life sciences clients of all sizes, Dechert LLP acts on a mix of transactions, litigation and corporate financings. Its corporate arm has acted on numerous IPOs for clinical-stage biopharma teams, as well as follow on and early funding rounds. Other corporate work includes M&A, monetization agreements, and business immigration. Disputes are a key part of the team’s workload, advising on product liability cases, antitrust disputes, and IP litigation, with an emphasis on small molecules cases. The team is co-led by Boston-based IP advisor Andrea Reid and New York-based David S Rosenthal, who advises on financings. New York-based Katherine Helm is a key name for patent litigation. Boston-based Brenda Sharton is also noteworthy for her advice to Moderna on EU data privacy breaches.

Practice head(s):

Andrea Reid; David S Rosenthal

Other key lawyers:

Katherine Helm; Brenda Sharton

Key clients

Agenus Inc.

Antios Therapeutics

Aquestive Therapeutics


BioDelivery Sciences

Brickell Biotech


Eli Lilly and Company

Endo Pharmaceuticals

Exo Therapeutics


Forbion Capital Partners


Homology Medicines

Johnson & Johnson

Kymera Therapeutics


Nimbus Therapeutics

Norgine B.V.


Piper Sandler & Co.

Purdue Pharma

Quest Diagnostics

Tectonic Therapeutics

Tiziana Life Sciences

Vigil Neuroscience

Work highlights

  • Advised Brickell Biotech in its $320m acquisition of the worldwide rights to Voronoi’s DYRK1A inhibitor platform.
  • Representing Eli Lilly and Company in global patent litigations involving Novartis Pharma AG.
  • Advised Tiziana Life Sciences on its migration from the London Stock Exchange to NASDAQ by inserting a new Bermuda-incorporated company as its parent company.

DLA Piper LLP (US)

Clients praise DLA Piper LLP (US)‘s litigation offering, nothing that its ‘expert testimony is second to none.’ Product liability cases make up the majority of the team’s high profile work, including advising Sanofi, Bayer, and Novo Nordisk in state and federal court. It also advises pharmaceutical companies on consumer class actions. Commercially, the team acts on a transaction’s full life cycle, encompassing due diligence, company formation, and regulatory issues. Financing is another area of expertise, both via private placements and capital markets offerings. Matthew Holian and Andrew Gilbert co-chair the team from Boston and New Jersey respectively. New York-based Loren Brown heads the litigation practice, with extensive experience on mass torts cases. Baltimore-based Howard Schwartz acts on financings, and Boston-based Katie Insogna acts on product liability matters.

Practice head(s):

Matthew Holian; Andrew Gilbert

Other key lawyers:

Loren Brown; Howard Schwartz; Katie Insogna; Chris Strongoski


‘DLA has an excellent Litigation team, led by Loren Brown. In particular, DLA’s Litigation practice in life sciences Daubert expert testimony is second to none. DLA is flexible in its billing and willing to work on a fixed fee basis.’

‘Chris Strongoski and his team were instrumental in our arbitration win.’


Key clients



Novo Nordisk/Victoza

Medtronic/Hernia mesh


Pfizer Inc./Greenstone LLC

Bristol-Myers Squibb Company

Pfizer Inc./Chantix

Global Pharmaceutical Company

Personal Genome Diagnostics

Kadmon Holdings

Fortress Biotech and Caelum Biosciences

Cowen and Company, LLC, William Blair & Company, L.L.C., BTIG, LLC and Stephens Inc.

Akoya Biosciences


Work highlights

  • Represented Sanofi in proceedings in the Fifth Circuit relating to its product Taxtoere’s potential risk of hair loss.
  • Representing Bayer in mass tort litigation involving implant contraceptive Essure.
  • Representing Novo Nordisk in federal and state court litigation involving allegations that Victoza causes pancreatic cancer and pancreatitis.

Mayer Brown

Mayer Brown strikes a strong balance between dedicated IP advice and M&A expertise, with the team, which features many attorneys with scientific backgrounds, advising on litigation for new and existing products, including Hatch-Waxman and biosimilar cases as well as advising on multibillion-dollar transactions for such notable clients as Nestle and Gilead Sciences. Beyond M&A, it advises on capital markets and licensing agreements. Lisa Ferri and Reb Wheeler co-lead the team, heading up the IP practice, acting on trial and appellate cases, and advising on transactions, respectively. Anna Pinedo and David Carpenter act on capital markets matters, and Henninger Bullock acts on product liability cases. All named lawyers are New York-based.

Practice head(s):

Lisa Ferri; Reb Wheeler

Other key lawyers:

Anna Pinedo; David Carpenter; Henninger Bullock

Key clients



Becton Dickinson

Endo International plc


Gilead Sciences


Nestlé Health Science



Work highlights

  • Advised Nestlé on the $2.6bn acquisition of Aimmune Therapeutics, Inc., the $2.3bn acquisition of Atrium Innovation and the $11.9bn purchase of Pfizer’s infant nutrition.
  • Advising Novartis AG on a range of issues as a member of its appellate litigation, transactions and cyber panels.
  • Representing Bristol-Myers Squibb on its $74bn acquisition of Celgene.

Morrison Foerster

Clients praise Morrison Foerster for its ‘key expertise in IP agreements and contracts'. The team also acts on joint ventures, M&A, including Protomer’s $1bn sale to Eli Lilly, and licensing agreements. Patents are a key strength of the team, with Palo Alto-based partner Catherine Polizzi known for creating patent strategies for emerging companies in the drug, therapy and medical technologies sectors. On the contentious side, the team acts on patent infringement cases ranging from biosimilars actions all the way to packaging-focused matters. Boston-based Michael Ward leads the team, with a growing emphasis on data analytics. Palo Alto-based Janet Xiao brings expertise in the Chinese IP market, and Washington DC-based former FDA Chief Counsel Stacy Cline Amin co-leads the compliance practice.

Practice head(s):

Michael Ward

Other key lawyers:

Catherine Polizzi; Janet Xiao; Stacy Cline Amin


‘They work well as a team, better than other firms I’ve experienced, bringing each other up to speed on projects so that talking to each of them results in them all being informed adequately to move work forward. They are also quite strategic and supportive in general.’

‘Catherine Polizzi is highly strategic, understands the business, provides advice but has a balanced understanding of the pros and cons of different decisions and strategies.’

‘Knowledgeable and responsive. Key expertise in IP, agreements, contracts that involve multiple parties from both public and private sectors. In my 30-year career, I have worked with a number of law firms (big and small) and rate this practice at Morrison & Foerster as one of the very best.’

‘Great customer service and communication. Able to explain complex legal issues, concerns and provide advice that is easily understandable to non-lawyers.’

‘The talent and humanity of the people at MoFo make this firm stand out. Every single attorney/paralegal I’ve interacted with has been bright, attentive, responsive, yet have a personality at the same time. There is diversity, especially at the more junior ranks.’

Key clients



Carlsmed, Inc.


Johnson & Johnson

McKesson Corporation

Orbimed Advisors

Rakuten Medical

Santen Pharmaceutical


Paul Hastings LLP

Paul Hastings‘ team excels in the patent litigation space, defending major patents in civil proceedings against leading pharmaceutical groups. It has particular expertise advising Japanese pharmaceutical groups, including Daiichi Sankyo and Mitsubishi Tanabe, on their US patent filings. The team also demonstrates strength on capital markets-related matters, including de-SPACs and follow-on offerings. The team has also expanded its regulatory practice, with the FDA team advising on product development, and the enforcement team advising on anti-corruption and government investigations, led by New York-based practice head Gary Giampetruzzi, who also handles white-collar crime. Also in New York, Bruce Wexler and Eric Dittmann are key names for IP, while Washington DC-based Nathan Sheers offers strong FDA expertise, and Palo Alto-based Jeff Hartlin acts on transactions.

Practice head(s):

Gary Giampetruzzi

Other key lawyers:

Bruce Wexler; Eric Dittmann; Nathan Sheers; Jeff Hartlin

Key clients

Johnson & Johnson


Merck & Co

Boehringer Ingelheim

Mitsubishi Tanabe Pharma Corporation

Actelion Pharmaceuticals

Spectrum Pharmaceuticals

Sucampo Pharmaceuticals, Inc.

Sorrento Therapeutics, Inc.

Redmile Group

Care DX, Inc.

Daiichi Sankyo


Jasper Therapeutics


Work highlights

  • Representing Mitsubishi Tanabe Pharma Corporation in enforcing the key Orange Book patents on Invokana and Invokamet.
  • Acting for Mitsubishi Tanabe Pharma Corporation in arbitration with Novartis relating to continued royalty payments.
  • Representing Daiichi Sankyo in a complex commercial dispute involving multiple parallel proceedings that concern cancer treatment technologies.


WilmerHale is known for its broad transactional strength, advising on major M&A, corporate financings, product licensing agreements and strategic alliances. It frequently acts for large product developers in their acquisitions, advising PerkinElmer on its $5.25bn acquisition of BioLegend. Beyond this, the team offers dedicated regulatory and litigation support, with an emphasis on IP strategy and defense. Stuart Falber and Lisa Pirozzolo co-lead the team from Boston and advise emerging biotech clients on corporate matters. New York-based David Bassett and Robert Gunther are key IP litigators, Boston-based Sarah Hogan offers strategic patent advice, and Craig Hilts, also Boston-based, advises on capital markets.

Practice head(s):

Stuart Falber; Lisa Pirozzolo

Other key lawyers:

David Bassett; Robert Gunther; Sarah Hogan; Craig Hilts


‘WilmerHale assembles a knowledgeable team with varying expertises to take on the most difficult and sprawling of matters They are a collaborative bunch, using a diversity of thought to make sure that a dispute is considered from all angles. They are willing to accept constructive criticism and always strive for excellence.’

Key clients

Apellis Pharmaceuticals

Astellas US


Bristol-Myers Squibb Company

CSL Behring

Cue Health

Editas Medicine

Exelixis, Inc.


Gilead Sciences


Iveric bio



Nabriva Therapeutics

Repare Therapeutics

Roche Molecular Systems

Sloan Kettering Institute for Cancer Research

Thermo Fisher Scientific

Xilio Therapeutics

Work highlights

  • Represented PerkinElmer in its acquisition of BioLegendfor $5.25bn in a combination of cash and stock.
  • Representing Voyager Therapeutics in the negotiation and execution of a significant license agreement with Pfizer.
  • Represented BMS and Pfizer in proceedings relating to their Eliquis patent.

Debevoise & Plimpton LLP

Debevoise & Plimpton LLP provides a mix of transactional and litigation services to its clients, made up of well known pharmaceutical groups and private equity investors. The team is playing a leading role in representing Purdue Pharma directors and investors in national opioid litigation, with  Maura Monaghan leading the group’s strategy across multiple states. Mark Goodman is also a well-regarded litigator, while Andrew BabKevin Rinker, and Jennifer Chu are key names for private equity investors. Washington DC-based Paul Rubin leads the team’s FDA practice, offering particular expertise with privacy-related compliance matters. Lawyers are in New York unless otherwise stated.

Practice head(s):

Andrew Bab; Mark Goodman; Maura Monaghan; Kevin Rinker; Paul Rubin

Other key lawyers:

Jennifer Chu

Key clients

Adare Pharmaceuticals

Allergan plc

Allergan plc

Centerbridge Partners

Certain former directors and shareholders of Purdue Pharma, Inc.

Clayton, Dubilier & Rice, LLC




Hospital Corporation of America and subsidiaries

JAB Holdings

Johnson & Johnson

J.P. Morgan Securities


Memorial Sloan Kettering Cancer Center

Merck KGaA

Morgan Stanley



Pfizer, Inc.

TPG Capital

ViiV Healthcare Limited

Work highlights

  • Advising Carlyle in its acquisition of a majority stake in Saama at an approximate value of $430m.
  • Representing certain former directors and shareholders of Purdue Pharma, Inc regarding prescription opioid litigation in various fora across the country.
  • Represented JAB Holding Company in dismissing trade secret, fraud, conversion, and unjust enrichment claims brought by Mars, Incorporated.

Foley Hoag LLP

Praised as an ‘organized, responsive and proactive’ group, Foley Hoag LLP is known for its transactional expertise, with an emphasis on capital markets and IP litigation services. Its ranks expanded during 2021, bringing in  new partners including regulatory attorney Bryant Godfrey from Arnold & Porter and transactional expert John Harre from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. The Boston-based team also handles work on patent portfolio management, with ‘incredibly effective’ partner Hathaway Russell representing Abbvie in key transactions and litigations. Jeffrey Quillien and Hemmie Chang co-lead the team, offering expertise on biotech matters and IP transactions respectively.

Practice head(s):

Hemmie Chang; Jeffrey Quillen


‘The Foley Hoag team is incredibly organized, responsive and proactive. They work hard to understand our priorities and they treat our projects with the corresponding level of care and attention. The team is well-trained, has relevant education and experience, and it is diverse.’

‘Hathaway Russell is incredibly effective. She is always available and directly engaged across a substantial prosecution docket. This speaks to her talent as a manager. Her teams have provided a very high level of support that has not wavered over the past ten years.’



Key clients

AbbVie, Inc.

Amgen Inc.

Becton, Dickinson (BD)


Biogen Inc.

Celsee, a Bio-Rad Laboratories company

Dana-Farber Cancer Institute

Dicerna Pharmaceuticals

Gilead Sciences, Inc.

Greenlight Biosciences

Harvard University

H.I.G. BioHealth Partners

La Jolla Pharmaceuticals

LegoChem Biosciences, Inc.

Myriad Genetics, Inc.

Organogenesis Inc.

Pear Therapeutics

Roche Diagnostics

Thermo Fisher Scientific

University of California

Work highlights

  • Advised GreenLight Biosciences in a $1.2bn SPAC business combination with Environmental Impact Acquisition Corp.  
  • Advised Dana-Farber Cancer Institute in patent litigation against Bristol-Myers Squibb and Ono Pharmaceutical relating to inventorship and ownership.
  • Advising HiFiBiO Therapeutics in an agreement to exclusively license its Galectin-9 program,

Gibson, Dunn & Crutcher LLP

IP litigation is at the core of Gibson, Dunn & Crutcher LLP‘s life sciences practice, with the team representing a number of biotech companies. The team is able to act on smaller civil infringements and appeal cases alike, as well as representing up to Supreme Court level Most notably, the team defended a patent challenge to Novartis’ MS medication Gilenya. In addition to IP, the team offers strong transactional support to large scale clients and further support on FDA investigations and compliance matters. Jane Love and Ryan Murr co-lead the team from New York and San Francisco respectively.

Practice head(s):

Jane Love; Ryan Murr

Key clients

Novartis Pharmaceuticals

EMD Serono and Pfizer

Smith + Nephew and ArthroCare

Advanced Accelerator Applications

Hema Biologics

Gilead Sciences


Roivant Sciences

Sage Therapeutics

Ultragenyx Pharmaceutical

Work highlights

    Kirkland & Ellis LLP

     Kirkland & Ellis LLP‘s ‘top-notch’ team advises on transactions and significant litigation. It is particularly known for its IP litigation practice, with partners Jay Lefkowitz in New York and Matt Rowen in Washington DC particularly regarded for their work on appellate litigations. It also acts on major product liability matters, with Lefkowitz advising GlaxoSmithKline, Torrent Pharmaceuticals and Amneal Pharmaceuticals on multiple consolidated class actions related to the drug Zantac. Chicago-based James Hurst is recognized for his work on Supreme Court cases and New York-based Patricia Carson is a key patent strategy advisor.

    Other key lawyers:

    Jay Lefkowitz; Matt Rowen; James Hurst; Patricia Carson


    ‘The Kirkland team has deep knowledge of the legal issues facing pharmaceutical developers, particularly in the litigation, product liability, and IP areas.’

    ‘Jay Lefkowitz and Matt Rowen are superior appellate litigators and have represented our industry association on critical litigation matters on behalf of the entire industry.’

    ‘The firm is staffed with top-notch lawyers who work well together and with their clients. We have had win-win secondment arrangements with the firm as well collaborations to develop and give a client exposure to diverse associates. They are also proactive in reaching out to discuss new regulatory or other developments that might impact the company.’

    Key clients

    Abbott Laboratories

    Abbvie Inc.

    Actavis Generics

    Akorn, Inc.

    Albertson Companies, Inc.

    Allergan plc

    Amneal Pharmaceuticals Inc.

    Arya Sciences Acquisition Corp. II

    Association for Accessible Medicines

    Barr Phamaceuticals

    Bristol-Myers Squibb Co.


    Cephalon Inc.

    Danaher Corp.

    Eagle Pharmaceuticals Inc.

    GlaxoSmithKline plc

    Hospira Inc.

    Impax Laboratories

    Lannett Co.

    Lupin Ltd.

    Sun Pharmaceuticals Industries Ltd.

    Teva Pharmaceuticals

    Torrent Pharmaceuticals Ltd.

    Upsher-Smith Laboratories LLC

    Norton Rose Fulbright

    Norton Rose Fulbright is known for its litigation practice, with a particular emphasis on antitrust cases. This includes New York-based Robin Adelstein advising Valent Pharmaceuticals on conspiracy cases relating to prescription drug price-fixing. Additionally, the team acts on product liability and patent litigation, with successful records in both. Data privacy is another area of focus for the practice, with the team serving as lead counsel to Abbot Laboratories on HIPAA, GDPR and CCPA compliance, with New York-based David Kessler a key name in this space. Dallas-based D’Lesli M Davis is recommended for mass tort cases, while Houston's Debbi Johnstone and Jonathan B Skidmore lead the global healthcare team.

    Practice head(s):

    Debbi Johnstone; Jonathan Skidmore

    Other key lawyers:

    David Kessler; D’Lesli M Davis; Robin Adelstein

    Key clients

    Mission Pharmacal

    Abbott Laboratories

    Valeant Pharmaceuticals International

    Southwest Texas Regional Advisory Council

    Pharmaceutical Strategies Group

    Standard Homeopathic Company and Hyland’s Inc.

    Bausch Health Companies Inc.


    Shareholder families of Purdue Pharma

    LongueVue Capital


    Work highlights

    • Successfully defended a Mission Pharmacal in an antitrust suit brought by a would-be generic manufacturer against the client and distributors of a kidney drug.
    • Serving as lead privacy counsel to Abbott Laboratories regarding CCPA, GDPR and HIPAA compliance.
    • Representing Valeant Pharmaceuticals in a dispute over an earn-out clause of a purchase agreement in Doctors Allergy Formula, LLC v. Valeant Pharmaceuticals International.

    O'Melveny & Myers LLP

    O'Melveny & Myers LLP is known for its broad portfolio of work, advising pharmaceutical companies on core transactions and representing them in litigations, alongside supplementing M&A with a focus on venture capital clients, with a presence in multiple pharmaceutical development markets. The contentious arm advises on product liability, antitrust and trade secrets cases. Most notably, the team is lead counsel for Johnson & Johnson in its Opioid-related cases. New York-based Lisa Pensabene and Ross Galin are key litigators focusing on IP. Scott Elliott leads transactions from San Francisco and Steve Brody leads the compliance and product liability teams from Washington DC. New York-based patent and medical tech litigator Hassen Sayeed is also recommended.

    Practice head(s):

    Steve Brody; Lisa Pensabene; Ross Galin; Scott Elliott

    Other key lawyers:

    Hassen Sayeed

    Key clients

    Amgen, Inc.



    Endo Pharmaceuticals

    JHL Biotech Inc.

    Johnson & Johnson

    Novartis Pharmaceuticals Corporation

    Progenics Pharmaceuticals, Inc.

    Samsung Bioepis

    ViiV Healthcare

    Work highlights

    • Advising for Johnson & Johnson on a myriad of national opioid cases.
    • Represented Onyx Therapeutics in product liability litigation regarding its cancer drug Kyprolis.
    • Represented Endo Pharmaceutical in a national antitrust monopolization case.

    Orrick, Herrington & Sutcliffe LLP

    Orrick, Herrington & Sutcliffe LLP‘s ‘deeply knowledgeable’ team offers distinct expertise defending IP rights, advising early-life companies on corporate matters, and providing FDA compliance advice. The team has continued expanding its ranks, notably welcoming health privacy expert Thora Johnson to the Washington DC from Venable LLP. Medical device manufacturers are a key client base for the group, with Washington DC-based co-head Anne Murray a known expert in this area. Silicon Valley-based Scott Iyama also heads the team and advises on VC investments and early-stage company IPOs.

    Practice head(s):

    Scott Iyama; Thora Johnson; Stephen Thau

    Other key lawyers:

    Anne Murray


    ‘The team members we work with at Orrick are deeply knowledgeable about the space. They work together very well as a team.’

    ‘Our primary contact is Scott Iyama, who is exceptional. His knowledge of the field is extensive and deep, and he has always been extremely supportive of our venture even when we were a very tiny company with little money.’

    Key clients

    Gilead Sciences

    Ramesh “Sunny” Balwani (Theranos)

    Clover Health

    SOC Telemed

    Zimmer Biomet

    ANI Pharmaceuticals

    K Health


    Novitium Pharma

    Virta Health

    Guide Therapeutics


    Scribe Therapeutics

    HCW Biologics

    Beacon Biosignals

    Work highlights

    • Representing Ramesh “Sunny” Balwani, former Theranos President and COO, in a major federal prosecution.
    • Representing Zimmer in obtaining declination letters from the U.S. Department of Justice and Securities and Exchange Commission.
    • Advised Clover Health on capital markets, M&A, antitrust, tax and compensation and benefits aspects of its $3.7bn SPAC merger with Social Capital Hedosophia.

    Proskauer Rose LLP

    Proskauer Rose LLP fields a team of IP experts with distinct expertise in the life sciences sector. Its litigators defend its clients’ patents and trade secrets, with particular expertise acting on behalf of biologics and biosimilars. Reviews of post-grant products are another unique speciality of the firm. Los Angeles-based Siegmund Gutman is particularly noteworthy, combining deep experience in Hatch Waxman litigation with industry ties in the biotech sector. Vice-Chair Fangli Chen is known for her patent prosecutions and strategic advice and is based in Boston. Also key are New York-based transactional attorney Robert Cantone and managing partner Daryn Grossman.

    Other key lawyers:

    Robert Cantone

    Key clients






    Absorption Pharmaceuticals

    Gilead Sciences

    Various Life Sciences Companies (Fangli Chen)

    Zion Pharma

    Tellus BioVentures



    Translate Bio

    Skadden, Arps, Slate, Meagher & Flom LLP

    Skadden, Arps, Slate, Meagher & Flom LLP‘s life sciences team acts for clients of large and small scale alike, advising pharmaceutical giants, such as Biogen and Johnson & Johnson, and emerging companies. The firm’s transactional offering is its highlight, with the team acting on major M&A deals as well as capital markets offerings. It also offers regulatory advice, with an emphasis on FDA compliance, and some litigation capacity, covering fraud and abuse, personal injury and criminal cases. Key lawyers include Boston-based Graham Robinson and Maya Florence, and Washington DC-based John Beisner and Jessica Miller.

    Other key lawyers:

    Graham Robinson; Maya Florence; John Beisner; Jessica Miller

    Baker Botts L.L.P.

    Baker Botts L.L.P. advises on patent strategy, as well as offering strong transactional support to clients. The team’s IP strength includes both strategy and litigation, with the team serving as long time advisors to clients like Genentech, and also has expertise advising on antitrust matters. Steve Lendaris heads the team from New York, and Austin-based Stephen Hash and Margaret Sampson advise on Hatch-Waxman litigation and patent strategy respectively.

    Practice head(s):

    Steve Lendaris

    Other key lawyers:

    Stephen Hash; Margaret Sampson


    ‘The Baker Botts team we worked with has a strong relevant scientific background. They are able to understand the science quickly and provide a patent strategy that suits the client’s needs. The team also adapts to the client’s needs in terms of billing, e.g., offering flexible fee arrangement or reduced fee structure.’

    ‘Steve Lendaris is the partner we usually interact with. He is smart, posed and strategic. He not only advises us from the patent lenses, but also from the business lenses. He can always find a way to detangle complex legal issues and help us come up with a well-rounded solution.’

    Key clients

    Genentech / Roche

    Novartis International AG / Sandoz Inc.

    Merck & Co., Inc.

    Oxford Nanopore Technologies Limited

    Horizon Pharma and Nuvo Pharmaceuticals

    FUJIFILM Cellular Dynamics, Inc.

    Editas Medicine

    Assertio Therapeutics

    Memorial Sloan Kettering Cancer Center

    UnitedHealth Group Incorporated / UnitedHealthCare, Inc. / Optum, Inc.

    Lyell Immunopharma

    Salem Partners LLC

    Royalty Pharma

    Natera, Inc.

    Sun Pharmaceuticals and Taro Pharmaceuticals

    Zydus Pharmaceutical, Inc./Cadila Healthcare LTD.

    PACT Pharma

    Renibus Therapeutics, Inc.

    Canopy Growth Corporation

    DisperSol Technologies LLC

    Avellino Lab USA, Inc.

    OncoNano Medicine, Inc.

    Columbia University

    University of Pennsylvania

    Wave Life Sciences Ltd

    Seagen, Inc.

    Work highlights

    • Representing Oxford Nanopore’s in a patent jury trial relating to its DNA sequencing platform.
    • Represented Assertio Therapeutics Inc. in its sale of Gralise to Alvogen for $127.5m.
    • Representing Sandoz in a dozen proposed class actions brought by plaintiffs against it and AbbVie relating to biosimilar market obstruction.

    Duane Morris LLP

    Duane Morris LLP is known for its corporate practice, providing expertise in M&A, licensing agreements and patent strategy for major life sciences companies. The firm is also strong in emerging companies work, with strong connections both to US-based venture capital firms as well as with pharmaceutical groups in East Asian markets. Miami-based Driscoll Ugarte is well regarded for his understanding of ‘subtleties in a deal.’ Other team leaders include Dana Ash and Shannon Sutherland in Philadelphia, Frederick Ball and Jonathan Lourie in Boston, Vicki Norton in San Diego and Patrick Gallagher in Boca Raton.

    Practice head(s):

    Dana Ash; Frederick Ball; Patrick Gallagher; Jonathan Lourie; Vicki Norton; Driscoll Ugarte; Shannon Sutherland

    Other key lawyers:

    Sean Zabaneh


    ‘Team is very efficient and willing to give definitive answers on complex matters.’

    ‘They are responsive and practical. Patrick Gallagher is a great IP strategist. Sean Zabaneh is a top-notch litigator.’

    ‘This team is exceptional in every way. Most importantly they talk to each other, are always on the same page and respond to the client in a very timely fashion. The team was technological advanced and client-friendly.’

    ‘The partner on my engagement, Driscoll Ugarte was invaluable to us. He responded all hours of the day or night including vacation. He is exceptionally knowledgeable and offered advice on all aspects of our engagement. Structural as well as economics and subtleties in the deal we’d have not considered. He then represented us to the other side of the transaction and influenced them to see our point of view. He is a remarkable individual.’

    ‘Have been working with Driscoll Ugarte for years. He is very responsive and thorough.’

    ‘They provide timely, relevant information to clients in a straightforward and cordial way. They always timely return calls and emails, and they are available around the clock when an emergency arises.’

    ‘They understand their clients’ business, not just the industry in which the client operates.’

    Key clients

    Artsana SPA

    HTL Strefa

    Allele Biotechnology

    Wright Medical

    Tornier, Inc.

    PeriphaGen, Inc.

    Stryker Corporation

    SIRPant Immunotherapeutics, Inc.

    Waypoint Orthopedics, Inc.

    NephroDI Therapeutics, Inc.

    Allevi Inc.

    Artsana SPA

    HTL Strefa

    Allele Biotechnology

    Wright Medical

    Tornier, Inc.

    PeriphaGen, Inc.

    Stryker Corporation

    SIRPant Immunotherapeutics, Inc.

    Waypoint Orthopedics, Inc.

    NephroDI Therapeutics, Inc.

    Allevi Inc.

    Work highlights

    • Represented Artsana in the CPSC recall of Infant Lounger. Recall of over 3,000,000 newborn loungers, one of the largest CPSC product recalls in recent history.
    • Advising Allele on patent strategy and management for innovative stem cell green fluorescent protein (GFP) technologies.
    • Advised on the acquisition of Ology Bioservices by Resilience.

    Fenwick & West LLP

    Fenwick & West LLP combines a strong transactional unit focused on licensing and collaboration agreements, with a dedicated IP litigation unit. It frequently advises early to mid-life companies on deals with larger businesses, such as its advice to Metagenomi on its collaboration agreement with Moderna. The team also advises on standard M&A and joint ventures. Melanie Mayer, Stefano Quintini and Matthew Rossiter co-head the team from Seattle, Mountain View and San Francisco respectively. Also key are capital markets experts Robert Freedman in San Francisco and Seattle’s Amanda Rose.

    Practice head(s):

    Melanie Mayer; Stefano Quintini; Matthew Rossiter

    Other key lawyers:

    Robert Freedman; Amanda Rose; Effie Toshav; Jake Handy; James Trainor; Jeffrey Oelke; Robert Counihan

    Key clients

    Almirall, LLC

    Atara Biotherapeutics, Inc.

    Devoted Health, Inc.

    DICE Therapeutics

    KaliVir Immunotherapeutics

    Lycia Therapeutics, Inc.


    Meril Life Sciences Pvt. Ltd. and Meril, Inc.

    Novo Nordisk A/S and Novo Nordisk Inc.

    Quest Diagnostics Investments

    Scribe Therapeutics Inc.

    Seattle Genetics, Inc.


    Sonoma Biotherapeutics

    Veracyte, Inc.

    Work highlights

    • Represented Metagenomi in a multi-year strategic research and development collaboration with Moderna Inc.
    • Represented Sema4 in its $2bn definitive business combination agreement with CM Life Sciences.
    • Representing Novo Nordisk A/S and Novo Nordisk Inc. in Hatch-Waxman litigation.

    Greenberg Traurig, LLP

    The team of ‘consummate professionals’ at Greenberg Traurig LLP is known for its expertise in transactions and product liability cases in the life sciences sphere. It has notably advised Huadong Medicine co. on a number of key collaboration agreements in both the antibody-drug and cancer therapy sectors. IP is another strength for the firm, in both contentious and advisory contexts. David Dykeman and Wayne Elowe co-lead the team from Boston and Atlanta respectively. Atlanta-based Lori Cohen is also notable for her litigation ability.

    Practice head(s):

    David Dykeman; Wayne Elowe

    Other key lawyers:

    Lori Cohen


    ‘The key capabilities are that any member of the team captures the legal challenge straight away and focuses on serving the client as efficient as possible.’

    ‘David Dykeman and the healthcare team in Boston are phenomenal. I can’t say enough good things about them – and just how competent and complete an organization they are – the team approach to solutions. They are just consummate professionals – heads and shoulders above all of their peer firms.’

    ‘Just from a legal counsel perspective the highest quality we can get.’

    Key clients

    Huadong Medicine Co., Ltd.

    BioTelemetry, Inc.

    Medtronic, Inc.

    Teva Pharmaceuticals USA, Inc.

    Memic Innovative Surgery

    Elios Vision

    Third Pole Therapeutics

    Provention Bio, Inc.

    IlluminOss Medical, Inc.

    Aspira Women’s Health (formerly Vermillion)

    PAVMed, Inc.

    Miromatrix Medical

    RedHill Biopharma

    Entrinsic bioscience

    Work highlights

    • Represented Huadong Medicine Co., Ltd in a strategic collaboration recently entered into with ImmunoGen, Inc.
    • Represented BioTelemetry in connection with its sale to Koninklijke Philips NV.
    • Representing Medtronic in product liability litigation.

    Haynes and Boone, L.L.P.

    Haynes and Boone, L.L.P. offers a strong emphasis on genetics and precision medicine, with a growing presence in the personalized medicine space. It provides IP services for these clients, both in contentious matters and on transactions, such as representing Teneobio in its $900m sale to amgen. The team’s San Francisco office is particularly strong, with team co-head Roger Kuan particularly known for his emerging companies work in the digital health and bioprinting sectors, while Jason Novak is also recommended for patent litigation. Benjamin Pelletier joined from  Venable LLP in January 2021.

    Practice head(s):

    Roger Kuan; Jason Novak; Benjamin Pelletier; Randy Peak

    Other key lawyers:

    Michael Smith


    ‘I’ve enjoyed my time with Jason Novak. He is a caring, empathetic, and committed source of counsel. Jason brings in the right people for our needs at the right time. He is transparent with expectations and clear in direction.’

    ‘Michael Smith has displayed the same level of professionalism.’

    Key clients

    TeneoBio, Inc.

    GRAIL, Inc.

    InterVenn Biosciences

    Volumetric Biotechnologies

    Berkeley Lights, Inc.

    Mekonos Inc.

    Work highlights

    • Represented TeneoBio, Inc. in connection with its acquisition by Amgen.
    • Advised Volumetric in its sale to 3D Systems to help advance research in life science technology and 3D printing.
    • Advising InterVenn Biosciences on ongoing patent portfolio management, prosecution, and counseling.

    Jones Day

    Jones Day leverages its global legal network to provide excellent services to both domestic and internationally-based life sciences groups. It offers regulatory and transactional advice in addition to providing major litigation support. The team notably advised Takeda Pharmaceuticals on Hatch-Waxman litigation regarding three of its diabetes products. The team is led by Washington DC-based Kenneth Field and Alexis Gilroy, alongside Heather O’Shea in Chicago. Boston-based Maureen Bennett is also recommended for advice on clinical trials and research agreements.

    Practice head(s):

    Kenneth Field; Alexis Gilroy; Heather O’Shea

    Other key lawyers:

    Maureen Bennett

    Key clients

    Astellas Pharma Inc.

    Johnson & Johnson and DePuy Orthopaedics

    Takeda Pharmaceuticals


    Merck & Co.

    NGM Biopharmaceuticals, Inc.

    Purdue Pharma


    STERIS Plc

    Work highlights

    • Advised STERIS plc in its $3.6 billion acquisition of Cantel Medical Corp.
    • Represented Takeda Pharmaceutical Company Ltd. in a Hatch-Waxman Act dispute against generic versions of three diabetes products.
    • Advising the International Clinical Research Organization on regulatory issues.

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. has a combined focus on transactions, capital markets and IP matters. The practice offers full life cycle support for companies, advising clients such as Viela Bio on its spin-out, IPO and eventual sale to Horizon Therapeutics. Based out of Boston, the group is led by four attorneys. Jonathan Kravetz and Megan Gates both advise on capital markets matters, William Whelan acts on transactions, and Lewis Geffen represents emerging companies.

    Practice head(s):

    Jonathan Kravetz; William Whelan; Megan Gates; Lewis Geffen

    Key clients


    Myriad Genetics, Inc.


    Johnson & Johnson

    BeiGene, Ltd.

    Janssen Pharmaceuticals

    Intra-Cellular Therapies, Inc.

    Biogen Inc.

    Viela Bio, Inc.


    Brooks Automation

    University of California

    10X Genomics

    DermTech, Inc.

    Evofem Biosciences, Inc.

    Dare Biosciences

    Fulgent Genetics, Inc.

    Exagen, Inc.

    FASCinate Therapeutics

    Inhibrx, Inc.

    Work highlights

    • Represented Viela Bio, Inc. in its $3.05bn sale to Horizon Therapeutics plc.
    • Represented Cardurion Pharmaceuticals, Inc. in its private investment of up to $300m from Bain Capital.
    • Represented biotechnology company BeiGene, Ltd. in its collaboration and license agreement Novartis Pharma AG for anti-PD-1 antibody tislelizumab.

    Paul, Weiss, Rifkind, Wharton & Garrison LLP

    Paul, Weiss, Rifkind, Wharton & Garrison LLP is known for its patent work, offering both strategic advice and representation in key litigation. It is particularly noteworthy for its work in the biologic medicine and biosimilars space, advising Amgen on a number of biologic patent cases. The team also offers strong transactional support as part of its top-tier high-value M&A offering. Nicholas Groombridge chairs the litigation group, having led the work for Amgen. Also noteworthy are Catherine Nyarady and Eric Alan Stone . All named lawyers are New York-based.

    Practice head(s):

    Nicholas Groombridge

    Other key lawyers:

    Catherine Nyarady; Eric Alan Stone

    Key clients

    10x Genomics



    Gilead Sciences

    Becton, Dickinson & Company (BD)

    Henry Schein


    Portola Pharmaceuticals

    Carolina Liquid Chemistries Corporation

    PRA Health Sciences

    Chugai Pharmaceutical Co., Ltd

    Teladoc Health, Inc.

    Edwards Lifesciences

    Translate Bio

    Elanco Animal Health

    Vanda Pharmaceuticals

    Evolus, Inc.

    Reed Smith LLP

    Reed Smith LLP is particularly known for transactional work, advising clients on investments, divestitures and joint ventures, alongside drafting research and licensing agreements, advising a mix of clinical-stage biotech companies and pharmaceutical manufacturers. Capital markets, IP and government investigations are other key parts of the practice’s offering. Princeton-based Betty Yan and Melissa Geist co-lead the team, focusing on transactions and litigation respectively. Michael Sanders and Deborah Gunny are also recommended in the Century City office.

    Practice head(s):

    Betty Yan; Melissa Geist; Scot Hasselman

    Other key lawyers:

    Michael Sanders; Deborah Gunny; Katy Basile


    ‘Katy Basile is great – very responsive, really listens to our concerns and takes the time to explore all options with us. We have always had great results with Katy.’

    ‘Impressive commercial focus; practical approach to negotiation.’

    ‘Great domain knowledge and breadth, particularly with international agreements.’

    ‘Unfailing prompt, knowledgeable service in all aspects of life science.’

    ‘Outstanding prompt and knowledgeable service.’

    ‘The Healthcare: Life Sciences practice just one area of expertise that the firm has available to all clients. We deal with other areas of practice that provide great counsel to meet our ongoing needs. This is the true benefit of Reed Smith. Our engagement partner has the resources to bring to whatever issues arise.’

    ‘I have worked with quite a few law firms over the years and find that Reed Smith is incredibly responsive, finds the most beneficial solutions and goes out of their way to get things resolved in the most timely, effective manner possible.’

    White & Case LLP

    White & Case LLP‘s growing life sciences team advises clients on their major transactional and contentious matters, representing a mix of emerging companies and life sciences giants. It is particularly known for its antitrust expertise, providing both support in mergers and direct anti-competitive behavior litigation expertise. The team is led by Peter Carney out of Washington DC, with prior experience as the head of the firm’s competition group. Also notable are New York-based patent litigator Colleen Tracy James and competition litigator Robert Milne.

    Practice head(s):

    Peter Carney

    Other key lawyers:

    Colleen Tracy James; Robert Milne

    Key clients




    CM Life Sciences

    Boston Scientific

    Gilead Sciences

    Hikma Pharmaceuticals

    Johnson & Johnson

    Myriad Genetics

    Novartis Pharma

    Novasep Holding

    Otsuka Pharmaceuticals


    Samsung Bioepis


    Winston & Strawn LLP

    Winston & Strawn LLP stands out for its litigation expertise, advising on a blend of IP and product liability matters. Its product liability team has been involved in a blend of opiate-related cases, notably acting for Hikma Pharmaceuticals in Ohio, and other class actions. Transactions are another area of expertise, supplemented by a strong antitrust focus. Washington DC-based Charles Klein is a key name for patent litigation and Los Angeles-based Nimalka Wickramasekera is an expert on medical device cases. The team is co-led by Chicago-based David Dahlquist and DC-based Reed Stephens.

    Practice head(s):

    David Dahlquist; Reed Stephens

    Other key lawyers:

    Charles Klein; Nimalka Wickramasekera

    Key clients

    Abbott Laboratories

    Alphatec Holdings

    Hikma Pharmaceuticals

    Monsanto Company

    MSN Laboratories

    Otsuka America Pharmaceutical, Inc.

    Work highlights

    • Representing Hikma in the national opiate litigation.
    • Representing Abbott Laboratories in a series of product liability lawsuits alleging that cow milk-based preterm infant formula products cause a gastrointestinal disorder in premature infants
    • Represented Sandoz in patent proceedings for its drug Otezla.